Consider the Benefits of New Meds to Prevent Chemo-Induced Nausea and Vomiting

You'll see more players join the crowded field of neurokinin-1 antagonists for chemotherapy-induced nausea and vomiting (CINV).

IV aprepitant (Cinvanti, sin-VAHN-tee) and IV rolapitant (Varubi, vuh-ROO-bee) will join IV fosaprepitant (Emend). There are also 3 ORAL meds...aprepitant (Emend, etc), rolapitant (Varubi), and netupitant combined with the 5-HT3 antagonist palonosetron (Akynzeo).

Expect neurokinin-1 antagonists to be included in HIGHLY and some MODERATELY emetogenic chemotherapy protocols to prevent addition to a 5-HT3 antagonist (ondansetron, etc), dexamethasone, and possibly olanzapine (Zyprexa, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals